Sebastian C Simon, Glazer William, Buckley Peter F
Department of Psychiatry, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA.
Curr Med Chem. 2004 Feb;11(3):329-42. doi: 10.2174/0929867043456025.
Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.
毫无疑问，在过去十年中，精神分裂症的药物治疗发生了巨大变化。大型双盲安慰剂对照试验推动了每一种新型抗精神病药物的问世。然而，由于第二代抗精神病药物之间长期比较研究相对较少，存在信息滞后的情况。在我们等待此类证据的同时，自然主义研究有助于提供有关这些新型药物在临床实践中的使用模式、患者反应和耐受性的有用信息。本综述介绍了每种第二代抗精神病药物的代表性研究，这些研究说明了自然主义研究对我们理解精神分裂症不断发展的药物治疗的贡献。
